Last reviewed · How we verify
SUM-101
At a glance
| Generic name | SUM-101 |
|---|---|
| Sponsor | European Vaccine Initiative |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Challenge Study to Assess the Blood-stage Efficacy of Full-length SUM-101 Malaria Vaccine Candidate (PHASE1)
- Safety and Immunogenicity of SUM-101 Malaria Vaccine in Children and Infants Living in Burkina Faso (PHASE1)
- Assessment of the Malaria Vaccine Candidate SumayaVac-1 in Healthy Adults Aged 18-45 Years Living in a Malaria Endemic Country (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SUM-101 CI brief — competitive landscape report
- SUM-101 updates RSS · CI watch RSS
- European Vaccine Initiative portfolio CI